ASX:MSBBiotechs
Mesoblast (ASX:MSB) Shares Rally Meets Persistent Cash Burn
The market has Mesoblast trading around A$2.41 after a choppy week that left the stock down about 4% over seven days but still up double digits over one and three months. That price action suggests investors are torn between excitement over the story and concern about the cost of pursuing that growth.
The main takeaway from this earnings release is straightforward. Mesoblast reported its first full commercial year of RYONCIL revenue at US$115 million, yet still posted a net loss of US$57.5...